- Cart - 0 item(s)
- $0.00
Your shopping cart is empty!
- Chemistry
- Bioactive Molecules
- Anti-infection
- Apoptosis
- Autophagy
- Cell Cycle/DNA Damage
- Cytoskeleton
- Epigenetics
- GPCR/G Protein
- Immunology/Inflammation
- JAK/STAT Signaling
- MAPK/ERK Pathway
- Membrane Transporter/Ion Channel
- Metabolic Enzyme/Protease
- Neuronal Signaling
- NF-κB
- PI3K/Akt/mTOR
- PROTAC
- Protein Tyrosine Kinase/RTK
- Stem Cell/Wnt
- TGF-beta/Smad
- Vitamin D Related/Nuclear Receptor
- Others
- Methylation
- Cytoskeletal Signaling
- Natural Products
- Alkaloids
- Amino acid
- Anthraquinones
- Cerebrosides
- Chalcones
- Coumarins
- Diterpenoids
- Flavonoids
- Iridoids
- Lignans
- Lipids
- Miscellaneous
- Monoterpenoids
- Other terpenes
- Phenols
- Phenylpropanoids
- Quinones
- Saccharides
- Sesquiterpenoids
- Steroids
- Tetraterpenoids
- Thiophenes
- Triterpenoids
- Xanthones
- Polyphenols
- Stibene glucosides
- Oligose
- Anthocyanins
- Miscellaneous
- Chromones
- Terpenoids
- Indoles
- Procyanidins
- Aliphatics
- Botanical Cyclopeptides
- ADCs
- Antibodies
- Multiplex IHC
- Material Science
- Others
[CAS NO. 834153-87-6] (R)-Elagolix
| Ships within | Stock | Price | Qty | Total |
Please click "REQUEST A QUOTE" button if there is no stock, or you need other sizes or custom synthesis.
| Catalog: | HY-14789 |
| Brand: | MCE |
| CAS: | 834153-87-6 |
Overview
| MDL | - |
|---|---|
| Molecular Weight | 631.59 |
| Molecular Formula | C32H30F5N3O5 |
| SMILES | FC1=C(C2=C(C)N(CC3=C(C(F)(F)F)C=CC=C3F)C(N(C[C@](C4=CC=CC=C4)([H])NCCCC(O)=O)C2=O)=O)C=CC=C1OC |
Summary
Elagolix is a highly potent, selective, orally-active, short-duration, non-peptide antagonist of the gonadotropin-releasing hormone receptor (GnRHR) (KD = 54 pM). Target: GnRH in vitro: Elagolix is a short-acting, nonpeptide, GnRH antagonist, administered orally, that unlike injectable depot GnRH agonists and antagonists, produces a dose-dependent suppression of ovarian estrogen production, that is, from partial suppression at lower doses to full suppression at higher doses. Elagolix is regarded as the frontrunner of a new class of GnRH inhibitors that have been denoted as second-generation, due to their non-peptide nature and oral bioavailability.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date | Phase |
|---|---|---|---|---|
| NCT04445025 | Colorado Center for Reproductive Medicine|AbbVie |
Infertility|Endometriosis
|
September 1, 2020 | Early Phase 1 |
| NCT04333576 | AbbVie |
Endometriosis
|
August 10, 2020 | Phase 3 |
| NCT00109512 | Abbott |
Endometriosis
|
April 2005 | Phase 2 |
| NCT03746535 | Yale University |
Endometriosis
|
July 1, 2022 | Early Phase 1 |
| NCT04856306 | Medstar Health Research Institute |
Heavy Menstrual Bleeding|Fibroid Uterus
|
April 12, 2021 | |
| NCT03271489 | AbbVie |
Heavy Menstrual Bleeding|Uterine Fibroids
|
September 13, 2017 | Phase 3 |
| NCT03343067 | AbbVie |
Endometriosis
|
December 27, 2017 | Phase 3 |
| NCT02691494 | AbbVie |
Uterine Fibroids|Heavy Menstrual Bleeding
|
February 3, 2016 | Phase 3 |
| NCT02925494 | AbbVie |
Uterine Fibroids|Heavy Menstrual Bleeding
|
September 14, 2016 | Phase 3 |
| NCT04060992 | University of Southern California |
Ovulation; Failure or Lack of
|
October 1, 2019 | Phase 4 |
| NCT04039204 | Wake Forest University Health Sciences|University of North Carolina, Chapel Hill|Stanford University |
Endometriosis|Unexplained Infertility
|
January 15, 2022 | Phase 2 |
| NCT00619866 | AbbVie |
Endometriosis, Pain
|
February 19, 2008 | Phase 2 |
| NCT01441635 | AbbVie (prior sponsor, Abbott)|AbbVie |
Heavy Uterine Bleeding|Uterine Fibroids
|
September 8, 2011 | Phase 2 |
| NCT01760954 | AbbVie |
Endometriosis
|
December 28, 2012 | Phase 3 |
| NCT01817530 | AbbVie |
Heavy Uterine Bleeding|Uterine Fibroids
|
April 8, 2013 | Phase 2 |
| NCT03951077 | AbbVie |
Polycystic Ovary Syndrome
|
August 12, 2019 | Phase 2 |
| NCT00973973 | AbbVie |
Endometriosis, Pain
|
October 12, 2009 | Phase 2 |
| NCT01620528 | AbbVie (prior sponsor, Abbott)|AbbVie |
Endometriosis
|
May 22, 2012 | Phase 3 |
| NCT00437658 | AbbVie |
Endometriosis
|
December 11, 2006 | Phase 2 |
| NCT04614246 | Bayer |
Endometriosis
|
January 29, 2021 | Phase 2 |
| NCT03886220 | AbbVie |
Uterine Fibroids
|
April 12, 2019 | Phase 4 |
| NCT02654054 | AbbVie |
Uterine Fibroids|Heavy Menstrual Bleeding
|
December 22, 2015 | Phase 3 |
| NCT04173169 | Yale University|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|University of Colorado, Denver|Northwestern University|University of North Carolina |
Infertility|Endometriosis
|
March 15, 2022 | Phase 3 |
| NCT00797225 | AbbVie |
Endometriosis
|
November 26, 2008 | Phase 2 |
| NCT03213457 | AbbVie |
Endometriosis
|
July 7, 2017 | Phase 3 |
| NCT01403038 | AbbVie (prior sponsor, Abbott)|Neurocrine Biosciences|AbbVie |
Folliculogenesis
|
June 2011 | Phase 1 |
| NCT02143713 | AbbVie |
Endometriosis
|
May 27, 2014 | Phase 3 |
| NCT01931670 | AbbVie |
Endometriosis
|
September 9, 2013 | Phase 3 |
| NCT05038878 | Icahn School of Medicine at Mount Sinai|AbbVie |
Mild Autonomous Cortisol Excess
|
July 6, 2021 | Phase 4 |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
Solvent & Solubility
DMSO : ≥ 100 mg/mL ( 158.33 mM )
* "≥" means soluble, but saturation unknown.
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 1.5833 mL | 7.9165 mL | 15.8331 mL |
| 5 mM | 0.3167 mL | 1.5833 mL | 3.1666 mL |
| 10 mM | 0.1583 mL | 0.7917 mL | 1.5833 mL |
Synonyms
Arctom is a premier supply platform offering over 600K unique items of Building Blocks, Bioactive Molecules, Natural Products, ADC PEG Linkers, Antibodies, and other Research Chemicals for global pharmaceutical, biotech, university, and industrial customers. We accelerate your research by providing better and faster purchasing experience & services.